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Abstract Magnetic resonance enterography (MRE) is fast
becoming the first-line radiological investigation to evaluate
t h es m a l lb o w e li np a t i e n t sw i t hC r o h n ’s disease. It can
demonstrate both mural and extramural complications. The
lack of ionizing radiation, together with high-contrast reso-
lution, multiplanar capability and cine-imaging make it an
attractive imaging modality in such patients who need pro-
longed follow-up. A key question in the management of
such patients is the assessment of disease activity. Clinical
indices, endoscopic and histological findings have tradition-
ally been used as surrogate markers but all have limitations.
MRE can help address this question. The purpose of this
pictorial review is to (1) detail the MRE protocol used at our
institution; (2) describe the rationale for the MR sequences
used and their limitations; (3) compare MRE with other
small bowel imaging techniques; (4) discuss how MRE
can help distinguish between inflammatory, stricturing and
penetrating disease, and thus facilitate management of this
difficult condition.
Main Messages
￿ MR enterography (MRE) is the preferred imaging investiga-
tion to assess Crohn’s disease. T2-weighted, post-contrast
and diffusion-weighted imaging (DWI) can be used.
￿ MRE offers no radiation exposure, high-contrast resolution,
multiplanar ability and cine imaging.
￿ MRE can help define disease activity, a key question in the
management of Crohn’s disease.
￿ MRE can helpdistinguish between inflammatory, stricturing
and penetrating disease.
￿ MRE can demonstrate both mural and extramural
complications.
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Introduction
Magnetic resonance enterography (MRE) is a radiological
technique that has evolved in the last decade. It involves the
use of magnetic resonance imaging (MRI) to assess the
small bowel, following distension with an oral contrast
agent. The advantages of this technique are that it involves
no ionising radiation, is capable of multi-planar imaging,
affords high-contrast resolution (with more detailed evalua-
tion of bowel wall changes) and allows for cine-imaging. Its
main indication at present is to evaluate small bowel in-
volvement in patients with Crohn’s disease (CD).
CD is a chronic inflammatory bowel condition with onset
usually in young adulthood. Twenty to thirty percent of
patients are younger than 20 years old. The prevalence in
the UK is estimated to be about 150 cases per 100,000
population [1]. It can involve any part of the gastrointestinal
tract. The small bowel, in particular the terminal ileum, is
most commonly involved but perianal disease can occur in
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DOI 10.1007/s13244-012-0154-3up to 40%. It is characterised histologically by the presence
of non-caseating granulomas and trans-mural inflammation
within the bowel, leading to erosions, ulceration and inflam-
matory stenosis. Enteric sinuses, fistulae, mesenteric phleg-
mons and abscess collections may complicate penetrating
disease. With time, inflammation may become chronic
and eventually lead to the development of fibrostenotic
strictures.
The European Crohn’s and Colitis Organisation (ECCO)
has recently published a revised consensus on the diagnosis
and management of CD [2]. Based on a systematic review of
the literature, it recommends either computed tomography
(CT) or MRE/MR enteroclysis as the current standards for
assessing the small intestine due to their high diagnostic
accuracy. It states that radiation exposure should be consid-
ered when selecting techniques. MRE can be used to help
Table 1 Parameters for MRI protocol
Parameter (1) True FISP (2) Cine True FISP (3) Diffusion (4) T1 volumetric fat-saturated
sequence
a, b
(5) HASTE
b
Axial Coronal Coronal Axial Axial Coronal Axial Coronal
c
TR/TE (ms) 4.09/1.77 4.19/2.1 74/1.48 5,600/82 5.43/2.41 5.43/2.36 900/83 1,000/217
Flip angle (degrees) 53 70 63 – 10 10 150 139
Field of view (mm) 400 450 450 350 400 450 400 400
Parallel imaging factor 2 0 2 2 2 2 2 2
Section thickness (mm) 4 4 8 5 3 3 6 5
Intersection gap (mm) 0 3 1.6 0 0 0 0 0
Number of sections per stack 50 20 18 40-60 64 64 20 20
Breath-hold time per stack 18 14 Free breathing Free breathing 18 14 18 22
Number of stacks 2 or 3 1 1 2 2 or 3 1 2 or 3 1 or 2
Bandwidth (Hz) 454 488 965 1302 300 300 416 130
True FISP true fast imaging with steady state precession, HASTE half-Fourier acquired single shot turbo spin echo, TR repetition time, TE echo time
aThe axial and coronal sequences are performed before and following intravenous administration of gadolinium
bThese sequences are performed following intravenous spasmolytic (e.g. buscopan) unless contraindicated
cThe coronal HASTE sequence can be performed with fat saturation to help distinguish between submucosal fat and oedema
Fig. 1 Coronal True FISP image: normal bowel. The ‘black boundary’
artefact may be confused with bowel wall thickening (arrows)
Fig. 2 Coronal T1 fat-saturated post-contrast image: normal bowel
wall shows mild homogeneous enhancement
252 Insights Imaging (2012) 3:251–263categorise the relative components of inflammatory, pene-
trating or stricturing disease in each individual patient. This
advantage in combination with no radiation exposure makes
MRE an ideal investigation for repeat bowel imaging in
patients with CD.
A recent study looking into the diagnostic and therapeu-
tic impact of MRE in CD has shown that MRE significantly
increased the mean percentage confidence of clinicians for
the presence or absence of small bowel disease and changed
therapeutic strategy in 61% of patients [3].
The purpose of this pictorial review is to (1) detail the
MRE protocol used at our institution; (2) describe the ratio-
nale for the MR sequences used and their limitations; (3)
compare MRE with other small bowel imaging techniques;
(4) discuss how MRE can assist the clinician in problem
solving in CD.
MRE protocol
The patient is fasted for 4-6 h prior to the study. In adults,
oral contrast consists of at least 1-1.5 l of a 2.5% mannitol
solution mixed with 0.2% carob bean gum. This solution
acts as a hyperosmolar agent to draw fluid into the bowel. In
paediatric patients, the volume of oral contrast is adjusted
(between 300-1,000 ml) according to the weight of the
patient. Mannitol is a biphasic agent that appears as low
signal intensity on T1-weighted images and high signal
intensity on T2-weighted images. The patient drinks the oral
contrast agent at regular intervals over a period of approx-
imately 40 min prior to the study. The patient is imaged on a
1.5-T MRI scanner (Siemens, Erlangen, Germany), using a
phased array surface coil, either in the supine or prone
Fig. 3 Coronal fat-saturated HASTE image: normal bowel. Intralumi-
nal flow voids (arrow) are seen, as this sequence is sensitive to fluid
motion
Table 2 Comparison of imaging modalities in the evaluation of Crohn’s disease
Imaging Modality Advantages Disadvantages
Barium follow-through Good depiction of early bowel disease
compared to CTE/MRE
Radiation burden; time consuming, operator and
patient dependent leading to limited sensitivity;
difficulty in assessing extramural complications
Ultrasound No radiation; may show terminal ileal
disease well
Operator and patient dependent; comprehensive
examination is not possible; time consuming
CTE Fast (< 5 mins); greater spatial resolution than
MRE; multiplanar reformats are possible;
mural and extramural complications are seen
Radiation burden; early disease is not well seen;
cine imaging is not possible
MRE No radiation; high soft tissue contrast; multiplanar
ability; shows mural and extramural complications;
defines activity of disease; cine imaging is possible;
can combine with perianal imaging
Longer scan time than CTE (20 mins); early disease
is not well seen; suboptimal distention of proximal
small bowel
Enteroclysis (barium/CT/
MRI)
Very good distension; can identify early ulceration,
wall thickening, fistulae, sinus tracts
Radiation burden; invasive; time consuming
Nuclear medicine
techniques
a
Similar diagnostic accuracy to CTE and MRE Radiation burden; time consuming; poor localisation
(unless PET-CT)
Balloon enteroscopy Evaluate small bowel mucosa; biopsy is possible Requires sedation/anesthesia; extramural complications
not assessed; risk of pancreatitis, bleeding, small bowel
perforation
Capsule endoscopy Evaluate small bowel mucosa Cannot use in stricturing disease; battery exhaustion; poor
localisation; extramural complications are not assessed
CTE CT enterography, MRE MR enterography
aWhite cell scintigraphy, positron emission tomography
Insights Imaging (2012) 3:251–263 253position (if no stoma is present). Coronal sequences are
quicker to perform in the prone position, as there is a thinner
volume of tissue to image. Although prone imaging has
been shown to result in better small bowel distension, both
positions are equivalent with respect to lesion detection and
characterisation of changes in the bowel wall in CD [4].
With the exception of the cine and diffusion-weighted
sequences, all scans are breath-hold and carried out in both
the axial and coronal planes. The imaging parameters for
our MRE protocol, and the order the sequences are per-
formed in, are shown in Table 1.
Rationale for MR sequences used in MRE
The True FISP (fast imaging with steady state precession)
sequenceconsistsofabalancedgradientechosequencewhere
image contrast is dependent on T2*/T1 ratio. It gives high-
contrast, predominantly T2*-weighted images. True FISP
eliminates phase shifts caused by motion and thus both fluid
and blood appear bright. It is a fast acquisition due to a short
repetition time (TR) and echo time (TE) with each image
acquiredin afewhundredmilliseconds. Susceptibilityartefact
occurs with the presence of intraluminal gas or ferromagnetic
material, leading to image distortion. Off-resonance artefacts
occur in the presence of a non-uniform magnetic field, result-
ing in banding artefact (alternating stripes) at the periphery of
the image. Chemical-shift artefact results in a ‘black bound-
ary’ effect around structures (Fig. 1). This makes mesenteric
nodes and vessels more conspicuous but may impede assess-
ment of bowel wall thickening. This sequence provides good
delineation between the bowel and the mesentery.
Fig. 4 Example of mural thickening in active Crohn’s disease: a axial
True FISP image shows mural thickening in the distal ileum (arrow); b
coronal True FISP in a different patient (15 years old) shows extensive
jejunal small bowel wall thickening (arrows); this distribution of
disease is less common than distal/terminal ileum. Note the fibrofatty
proliferation in the adjacent mesentery
Fig. 5 Example of pseudosacculation: coronal True FISP image shows
two long skip lesions in the mid to distal ileum (asterisk) demonstrat-
ing mural thickening, luminal narrowing and prominence of the vasa
recta (arrowheads) with small nodes seen within the mesentery. There
are multiple pseudosacculations (arrows) on the antimesenteric border
due to asymmetric involvement of the bowel wall. Mesenteric fibro-
fatty proliferation separates the involved bowel loops. Appearances
suggest a mixture of active and fibrostenotic disease
254 Insights Imaging (2012) 3:251–263The cine True FISP sequence involves repeatedly imag-
ing the abdomen in the coronal plane sequentially from front
to back over a period of 2 min. Twenty images are acquired
in each coronal plane. Inflamed loops of bowel will demon-
strate decreased peristalsis. An inflammatory small bowel
stenosis should open up on cine imaging, compared with a
fibrotic stricture where the stenosis will be constant and
associated with more marked pre-stenotic dilatation.
Diffusion-weighted imaging (DWI) has recently been
added to our MRE protocol with parameters as shown in
Table 1. Three b values (b 0 0, 100 and 800) are used with
axial images through the upper and lower abdomen
obtained. The purpose of this is to help identify actively
Table 3 Comparison of active
inflammation and fibrostenotic
disease on MRE
Features on MRE Active inflammation Fibrostenotic disease
Mural thickness Moderate Mild
Mural enhancement Avid Mild
Stratified mural enhancement Yes Variable
Mural oedema Yes Mild/absent
Increased mesenteric vascularity/adenopathy Yes No
Mesenteric phlegmon, abscess Present in penetrating disease No
Fistulae Present in penetrating disease Sometimes present
Fibrofatty proliferation Sometimes present Yes
Fig. 6 Patient with active distal ileal Crohn’s disease: a) axial HASTE
image shows bowel wall is of intermediate signal (arrow) due to
submucosal oedema. Mesenteric oedema (asterisk) is also noted; b)
corresponding axial T1 fat-saturated post-contrast image shows avid
stratified pattern of mural enhancement (arrow)
Fig. 7 Patient with active distal colitis: a axial HASTE image shows
very high signal in the submucosa in keeping with oedema (arrow); b
corresponding axial T1 fat-saturated post-contrast image shows avid
stratified pattern of mural enhancement (arrow)
Insights Imaging (2012) 3:251–263 255inflamed loops of bowel by the presence of restricted diffu-
sion within the affected bowel wall.
The post-contrast sequence involves a three-dimensional
(3D)T1-weightedfat-saturatedspoiledgradientechosequence
(Fig. 2) performed 70 s following hand injection of 0.2 ml/kg
(0.1mmol/kg)intravenousGadotericacid(Dotarem,Guerbet).
Gadolinium is not given in patients with chronic renal impair-
ment, due to the potential long-term risk of nephrogenic sys-
temic fibrosis. A pre-contrast sequence is routinely performed.
Some institutions use a dynamic post-contrast coronal acqui-
sition; for example, a volume interpolated breath-hold exami-
nation(VIBE)canbeperformedinthearterial(30s—optional)
andportalvenous (60-70 s)phasesusingbolus triggeringonce
contrast reaches the descending aorta. With a 3D sequence, a
radiofrequency pulse excites a thick volume of tissue rather
than a thin 2D section, with increased spatial resolution. The
3D sequence is, however, sensitive to motion artefact. Bowel
peristalsisis reducedbythe priorintravenous administration of
a spasmolytic. This usually consists of 20 mg intravenous
hyoscine-N-butylbromide (buscopan). Buscopan is routinely
given unless contra-indicated (e.g. history of cardiac arrhyth-
mia, narrow angle glaucoma or prostatism). In instances when
this cannot be administered, 1 mg intravenous glucagon is
given asan alternative unless patients havea known hypersen-
sitivity to glucagon or a history of phaeochromocytoma.. The
purposeofthissequenceistoassessbowelwallandmesenteric
nodalenhancement andto evaluate for thepresence ofanyrim-
enhancing fluid collections.
The HASTE (half-Fourier acquired single-shot fast spin
echo) sequence is a fast sequence consisting of heavily T2-
weighted images. It is a pulse sequence with a very long
echo train, where each echo is individually phase encoded.
The partial Fourier technique assumes symmetry of raw data
in K-space, to reduce data acquisition time. However, this
results in a reduced signal-to-noise ratio. It is good at depict-
ing fluid, but other tissues with short T2 values are associ-
ated with blurring artefact. It is sensitive to intraluminal
flow voids (Fig. 3) and is thus performed after the intrave-
nous administration of a spasmolytic. The HASTE sequence
is used to assess for mural oedema. The optional use of fat
saturation on one of the T2-weighted sequences (either the
True FISP or HASTE sequence) allows differentiation be-
tween submucosal fat and oedema which both appear bright
on T2-weighted images. Fat saturation also increases the
conspicuousness of oedematous bowel loops.
Fig. 8 Example of fibrostenotic disease: coronal HASTE image shows
a stricture in the neoterminal ileum in a patient with previous ileocolic
resection; this is of intermediate to low signal due to little mural
oedema (arrows); there is pre-stenotic dilatation
Fig. 9 Patient with fibrostenotic disease: a coronal True FISP image
showing short fibrotic stricture (arrows) in the mid descending colon
with marked pre-stenotic dilatation; b corresponding homogeneous
mural enhancement is seen in this skip lesion (arrow)
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Other radiology techniques used to image the small bowel
include barium follow-through, CT enterography, ultrasound
and nuclear medicine techniques (such as positron emission
tomography [PET]-CTand white cell scintigraphy).
With regards to the use of PET or PET-CT in the evalu-
ation of CD, the sensitivity in the detection of active inflam-
mation ranges between 73% and 90% when compared with
clinical, endoscopic or biological markers of disease activity
[5, 6]. Using PET alone, there is poor disease localisation,
and specificity can sometimes be low [7], as other patho-
logical or physiological processes may lead to increased
bowel fluorodeoxyglucose (FDG) uptake. The main disad-
vantage of PET-CT is the use of ionising radiation; this is
clearly not ideal in young patients who may require repeated
imaging. It is also more time consuming to perform than CT
or MRI alone. Hence for these reasons, PET-CT is not
routinely used in the assessment of patients with CD.
A recent meta-analysis of 33 studies using ultrasound,
MRE, scintigraphy and CT in the diagnosis of CD, showed
no significant difference in the mean sensitivity [8]. All
these techniques showed a high sensitivity (> 84%) and
specificity (90%) on a per patient basis [8]. Hence the
preference is based on availability and consideration of
radiation exposure.
Enteroclysisisatechnique whereby oralcontrastisdirectly
infused into the small bowel via a nasojejunal catheter at a
highflowrate(e.g.80ml/min)inordertoobtainoptimalsmall
bowel distension. Depending on the oral contrast agent used
and preference of the radiologist, the small bowel can then be
imagedusingeitherfluoroscopy, CTorMRI.MRenteroclysis
gives better mucosal detail than MRE [9] and is thus more
likely to detect subtle aphthous or other types of mucosal
ulceration. However, in the assessment of ileal CD, MRE
has shown an equivalent accuracy and reproducibility to MR
enteroclysis [10].
In addition to ileocolonoscopy, the gastroenterologist can
use other techniques to evaluate the small bowel. Double
balloon enteroscopy can examine the whole of the small
bowel, eitherunder conscious sedation orgeneral anaesthesia.
Video (or wireless) capsule endoscopy (VCE) involves the
ingestion of a capsule that contains a camera and transmitter,
which is propelled along the bowel by peristalsis. A video
recorder carried on the patient records the signals and a
computer later processes the data. A recent meta-analysis
[11] looking at nine studies comparing VCE to other techni-
ques in the diagnosis of CD (i.e. ileocolonoscopy, CT enter-
ography/enteroclysis, push enteroscopy and MRI) showed
VCE gave a greater diagnostic yield due to its ability to detect
mucosal abnormalities. However VCE is not possible in stric-
turing disease, hence radiological imaging is usually required
first to exclude this (unless a patency capsule is used).
Table 2 shows the advantages and disadvantages of each
technique when compared with MRE.
Problem-solving in small bowel CD
The multidisciplinary team meeting (consisting of the radi-
ologist, gastroenterologist, histopathologist and surgeon) is
an important forum where imaging, histopathology and
clinical status of the patient can all be reviewed, in order
to determine the most appropriate management. The following
important questions can be addressed on MRE: (1) extent of
small and large bowel involvement at first presentation; (2)
distinction between active inflammatory and fibrotic stricturing
disease; (3) recognition of penetrating disease with the devel-
opmentofextramuralcomplications;(4)evaluationofresponse
to medical therapy; (5) detection of recurrent disease following
surgery. Each of these questions will be addressed in turn.
Extent of bowel involvement at first presentation
The hallmark of CD on cross-sectional imaging is bowel wall
thickening (Fig. 4a, b) (between 4 to 12 mm), usually in
association with luminal stenosis. Normal bowel wall thick-
ness, when adequately distended, should not exceed 3 mm.
Mural thickening can be appreciated on all sequences. The
commonest site of involvement is the terminal ileum (some-
times with contiguous disease in the caecum). Discontinuous
Fig. 10 Example of comb sign in active inflammation: coronal True
FISP image shows multiple linear low signal structures extending to
the bowel wall in keeping with engorged vasa recta (arrows) supplying
the thickened terminal ileum (asterisk). Note the fibrofatty proliferation
within the adjacent mesentery, separating the inflamed terminal ileum
from adjacent loops of bowel, with small mesenteric nodes also present
Insights Imaging (2012) 3:251–263 257skip lesions may be seen more proximally in the small bowel
or within the colon. If there is suboptimal distension (as is
sometimes the case, especially with jejunal loops), disease
may be overestimated or underestimated. Early disease, char-
acterised by mucosal changes only, may also not be appreci-
ated on MRE. The evaluation of all sequences may help
clarify the extent of bowel involvement, as fluid distension
in the small bowel will vary over time. Strictures can also be
distinguished from peristalsis on the cine sequence. Involve-
ment of the bowel wall may be symmetrical or asymmetrical,
where greater involvement of the mesenteric border leads to
pseudo-sacculation (Fig. 5). With repeated episodes of acute
inflammation, mesenteric fibrofatty proliferation (‘creeping
fat’/‘fat wrapping’) tends to develop along the mesenteric
border of the involved segment of bowel (Fig. 5); this is a
helpfuladditionalfeatureonMREdenotingthesiteofdisease.
Distinction between active inflammatory and stricturing
disease
A key question in the management of patients with CD is
the assessment of disease activity. Active inflammation
(characterised clinically by acute clinical symptoms and
raised inflammatory markers) is usually treated medically
(unless there are extra-mural complications), whilst fibroste-
notic disease (characterised by obstructive symptoms) often
requires surgery. In addition to dietary approaches, there are a
number of drugs that can be used to induce and/or maintain
remission in CD [12]. In the last decade, anti-tumour necrosis
factor alpha (TNF)-α antibodies (infliximab, adalimumab)
have become an established and highly effective treatment
for moderate to severe CD.
Endoscopy (with the use of an endoscopic severity score)
with or without biopsy can be used to directly assess the
degree of inflammation in the bowel. However, this is an
invasive technique, which is restricted to the colon and
distal 20-30 cm of ileum. There are several surrogate
markers for disease activity that clinicians have traditionally
used (including the Crohn’s Disease Activity Index [CDAI],
C-reactive protein [CRP] and more recently faecal markers
such as faecal calprotectin). All of these markers, however,
have limitations. In a meta-analysis of seven studies (140
patients) looking at MRI to determine disease activity, MRI
correctly graded disease activity in 91% of cases with frank
disease [13]. Recently, attempts have been made to derive an
MR-based activity score (using MR features such as mural
Fig. 11 Example of DWI in active inflammation: a axial T1 fat-
saturated post-contrast image shows thickened enhancing ileum with
typical stratified enhancement pattern (arrow); b corresponding DWI
(b0800) and c ADC map confirm restricted diffusion with persistent
high signal (arrow) on the DWI and low signal (arrow) on the ADC
map (ROI01,200)
b
258 Insights Imaging (2012) 3:251–263thickness and oedema) to assess disease activity, validated
with ileocolonoscopy and histology as the standard of ref-
erence [14, 15].
When using MRE to assess activity of disease, the follow-
ing featurescan be evaluated. Thesehave been summarised in
Table 3.
Degree of mural thickening
It has been shown [16] that active inflammation (as
defined by findings of inflamed mucosa or inflammatory
infiltrates on endoscopy or histopathology respectively)
has a greater degree of mural thickening on MRE
(Fig. 4a, b) compared with chronic inflammation or
fibrostenotic disease (mean maximal wall thickness
6.7 mm versus 3.3 mm respectively). A direct positive
correlation has been demonstrated between the degree of
acute inflammation on histopathology (defined by an
acute inflammatory score) and the degree of mural thick-
e n i n go nM R E[ 17]. This is not surprising as mural
thickening is probably due to a combination of oedema
and inflammatory infiltrates.
Bowel wall signal intensity on T2-weighted images
The affected bowel wall in active inflammation demonstrates
higher signal intensity on T2-weighted images due to the
presence of mucosal or submucosal oedema (Figs. 6a, 7a).
Good correlation has been shown between mural hyperinten-
sity on T2-weighted images, biological parameters (such as
CDAI and CRP) and histopathology [17, 18]. In fibrostenotic
disease, the bowel wall appears of lower signal due to the
presence of fibrosis (Figs. 8, 9a). Sometimes in chronic dis-
ease, submucosal fat deposition occurs, which is also of high
signal on T2-weighted images. As mentioned earlier, the use
of a fat-suppressed T2-weighted sequence can thus be helpful
in distinguishing submucosal fat from oedema.
Degree of mural enhancement
Active inflammation results in an increase in bowel wall
enhancement compared with adjacent uninvolved bowel
[19–23]. Less avid mural enhancement is seen in fibroste-
notic disease. Some studies have used dynamic contrast
enhanced MRI [20–23] to obtain either semi-quantitative
Fig. 12 Complications of
penetrating disease: a coronal
True FISP image showing an
enteroenteric fistula (arrows)
between an inflamed segment
of mid ileum (white asterisk)
and non-inflamed terminal ile-
um (black asterisk); b Axial
True FISP image in a different
patient showing an enterocuta-
neous fistula (arrows) between
a loop of inflamed thickened
small bowel (asterisk) and skin;
c axial True FISP image in a
different patient showing the
‘star’ sign between adjacent
loops of bowel, highly sugges-
tive of enteroenteric fistulae
(arrows); d coronal T1 fat sat-
urated post contrast image in a
different patient again showing
multiple converging enhancing
loops of small bowel suggestive
of enteroenteric fistulae
(arrows)
Insights Imaging (2012) 3:251–263 259or quantitative measurements of enhancement. Results suggest
thatinflamedbowelsegmentshavesteeperinitialenhancement
slopes, and faster volume transfer coefficients (Ktrans) [21,
23]. A linear relationship between the degree of bowel wall
enhancement and degree of inflammatory activity on histopa-
thology has, however, not been clearly established [17].
Pattern of mural enhancement
Active inflammation may show either increased mucosal
enhancement or a stratified pattern (Fig. 6b, 7b) of mural
enhancement [17, 18]. The latter is due to the presence of
submucosal oedema, where there is avid enhancement of the
mucosa and the muscularis propria/serosa but relatively
reduced enhancement of the submucosa. Chronic inflamma-
tion and fibrostenotic disease may show either a heteroge-
neous, homogeneous (Fig. 9b)[ 24] or stratified pattern of
enhancement [18]. It is postulated [17] that the stratified
pattern of enhancement seen in fibrostenotic disease may be
due to the presence of active disease on the background of
mural fibrotic change or the presence of mural fibrosis itself
(which theoretically would then show delayed enhancement).
Pre-stenotic dilatation
Dilatation can occur upstream to either an inflammatory
stenosis or fibrostenotic stricture (Fig. 9a, b). This is signif-
icant when the small bowel diameter is > 3 cm. As men-
tioned earlier, cine imaging is helpful in distinguishing
between active inflammatory and fibrotic strictures.
‘Comb’sign and mesenteric adenopathy
In active inflammation, the vascular arcades (vasa recta)
supplying the involved bowel segment become engorged.
Fig. 13 Complications of penetrating disease: coronal T1 fat-saturated
post-contrast image showing multiple enhancing skip lesions (arrows)
and enhancing mesenteric phlegmon (asterisk)
Fig. 14 Complication of penetrating disease: patient with active colitis
showing circumferential mural thickening and stratified mural en-
hancement of the proximal colon (asterisk), complicated by an ileop-
soas abscess (arrows)
Fig. 15 Complication of penetrating disease: patient with local perfo-
ration due to penetrating Crohn’s disease of the proximal colon—a
thick walled air-containing cavity is seen extending into the anterior
abdominal wall (arrows)
260 Insights Imaging (2012) 3:251–263These are straight vessels that extend perpendicular to the
bowel wall within the mesentery and resemble the teeth of a
comb. They appear as low signal linear structures on True
FISP images (Fig. 10) with enhancement post-contrast. Prom-
inent reactive enhancing mesenteric nodes (up to 8 mm in
short axis diameter) will also be seen in active inflammation
(Figs. 5, 10). If larger volume adenopathy is seen, the devel-
opment of lymphoma needs to be excluded.
Restricted diffusion
In the last 5 years, there have been several studies [25–27]
that have suggested that DWI may have an adjunctive role
in the assessment of disease activity in affected bowel.
Either visual assessment of DWI or quantitative assessment
of the ADC value can be made. Restricted diffusion in
affected bowel segments is more likely in active inflamma-
tion (Fig. 11a-c) compared to fibrostenotic disease [25–27].
Recognition of penetrating disease and development
of extramural complications
Sinus and fistula formation
Blindending sinus tracts andfistulae may develop inactive CD
due to transmural bowel inflammation and penetrating ulcera-
tion. Enteroenteric (Fig. 12a), enterocolic, enterovesical and
enterocutaneous(Fig.12b)fistulaemayarise.Theseareusually
well demonstrated on the True FISP and HASTE sequences
due to high signal fluid content within the tracts, but will also
be seen as rim-enhancing low-signal tracts on the post-contrast
images. The ‘star’sign (Fig. 12c, d) is where multiple converg-
ing loops of inflamed bowel are seen and is suggestive of
enteroenteric fistulae. It has been shown that MRE has an
overall sensitivity for sinus tracts and fistulae of >75% and
specificity of 100%, when compared with MR enteroclysis and
conventional enteroclysis as the reference standards [6].
Mesenteric phlegmon and abscess collections
Active inflammation can result in the formation of small
enhancing phlegmons within the mesentery (Fig. 13). Rim
enhancing heterogeneous abscess collections (Fig. 14) can
also develop within the abdomen, possibly secondary to
localised bowel wall perforation (Fig. 15). These abscesses
are important to identify, as antibiotics and/or percutaneous
drainage may be required.
Evaluation of response to medical therapy
MRE is a useful tool in the assessment of treatment response
following medical therapy. It has been shown that when MRI
is performed during an acute relapse and then in remission, a
reduction in both mural contrast enhancement and in mural
thickness in affected segments is seen [28]. However, luminal
stenosismay persist.Asstatedearlier, biologics suchasinflix-
imab and adalimumab have been used to treat patients with
CD resistant to other therapies with mucosal healing as a key
treatment goal. From our experience, MRE can be used to
show a significant reduction in inflammatory activity (as
demonstrated by reduced mural thickening, oedema and en-
hancement) following treatment with such agents (Fig. 16a,
Fig. 16 Typical example of response to treatment with a biologic: a
axial T1 fat-saturated post-contrast image shows a thickened avidly
enhancing segment of midileum with stratified pattern of enhancement
(arrows) in keeping with active inflammation; b axial T1 fat-saturated
post-contrast image following 8 months of infliximab shows inflam-
mation has been downstaged with reduction in mural thickening and
enhancement which is now homogeneous (arrows)
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predicted decrease in the degree of restricted diffusion. How-
ever, as yet there are no published papers on this subject.
Detection of recurrent disease following surgery
As the terminal ileum is the commonest site of disease in CD,
the majority of patients eventually requiring surgery typically
have an ileocolic resection. Stricturoplasties may also be per-
formed in short (< 3 cm) fibrotic strictures causing obstructive
symptoms. Patients are routinely re-evaluated by ileocolono-
scopy at 6-12 months post-resection. Post-surgical recurrence,
defined as the appearance of new lesions on endoscopy, radi-
ology or pathology, occurs in 80% of patients at the site of the
neoterminal ileum/anastomosis (Fig. 8) within the 1st year
following resection [29, 30]. Rutgeerts et al. [29] have shown
that patients with absent or very mild lesions on endoscopy
followingsurgeryhaveaverygoodprognosis,whereaspatients
with more severe lesions on endoscopy develop early clinical
recurrence. Limitations of ileocolonoscopy are that intubation
of the neoterminal ileum may not be possible due to stenosis,
more proximal small bowel disease will not be assessed and
extramural complications will not be demonstrated. Recently
both MR enteroclysis [31] and MR enterography [32]h a v e
been suggested as useful alternatives, showing good concor-
dance with ileocolonoscopy in the detection of recurrence and
in the differentiation of high and low risk patients.
Conclusion
Imaging has an important role in the management of CD.
Although various imaging modalities are available, MRE is
increasingly becoming the first line investigation for such
patients. It can be useful at both initial diagnosis and follow-
up. It is the preferred investigation due to its lack of ionising
radiation and its ability to depict both mural and extramural
complications. MRE can be performed prior to VCE in
excluding strictures where VCE can then be used to detect
subtle mucosal disease. In combination with blood and
faecal biomarkers and endoscopy, MRE can assist the treat-
ing clinician in distinguishing between inflammatory steno-
ses amenable to medical therapy and fibrostenotic disease
requiring surgery. The value of DWI remains to be defined,
but it may well have an adjunctive role in the assessment of
disease activity and response evaluation.
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